3Belch A, Kouroukis CT, Crump M, et al. A phase Ⅱ study of borte- zomib in mantle cell lymphoma: the National Cancer Institute of Cana- da Clinical Trials Group trial IND. 150. Ann Oncol, 2007,18 ( 1 ) : 116.
4Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in pa- tients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol, 2006,24( 13 ) :2105-2112.
5Liu S, Yuan Z, Zhang C, et al. Bortezomib-based treatment for re- lapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review. J Oncol Lett, 2012,4(2 ) :262-264.
3BREMER K, ROTH W. Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas [J] .Tumor Diagn Ther, 1996,17(1) : 1 - 6.
4JULIA A B B, KAREN L G. Bendamustine[J]. Drugs, 2001, 61(5) :631 - 638.
5HOFFKEN K, MERKLE K, SCHONFELDER M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase Ⅱ study[J ]. J Cancer Res Clin Oneol, 1998,124(11) :627 - 632.
6PONISCH W, MITROU P S, MERKLE K, et al. A randomized multicenter study of bendamustine/prednisone versus melphalane/prednisone in the primary treatment of multiple myeloma[J]. Blood, 1999, 94(10, Suppl. 1) : 123a.
7Swerdlow SH,Berger F,Pileri SA,et al.Lymphoplasmacytic lymphoma//Swerdlow SH,Campo E,Harris NL,et al.World Health Organization classification of tumoura.WHO classification of tumours of haematopoietic and lymphoid tissues.Lyon:IARC Press,2008:194-195.
8Viswanatha D,Foucar K.Hodgkin and non-Hodgkin lymphoma involving bone marrow.Semin Diagn Pathol,2003,20(3):196-210.
